MONDAY, March 15 (HealthDay News) -- In everyday clinical practice, the sirolimus-eluting stent may be superior to the zotarolimus-eluting stent in low-risk patients with coronary artery disease, according to the results of the SORT OUT III study published online March 15 in The Lancet. The findings were released to coincide with the Annual Scientific Session of the American College of Cardiology, held from March 14 to 16 in Atlanta.
Klaus Rasmussen, M.D., of the Aarhus University Hospital in Aalborg, Denmark, and colleagues randomized 2,332 individuals with coronary artery disease undergoing percutaneous coronary intervention between January 2006 and August 2007 to treatment with sirolimus-eluting or zotarolimus-eluting stents.
The researchers found that, at nine months, individuals with the zotarolimus-eluting stent had a higher risk of adverse cardiovascular outcomes (cardiac death, myocardial infarction and target vessel revascularization) than those who received the sirolimus-eluting stent (6 percent versus 3 percent), and this difference was sustained at 18 months (10 percent versus 5 percent). All-cause mortality was the same for both stent groups at nine months but significantly higher for the zotarolimus-eluting stent group at 18 months (4 percent versus 3 percent).
"The sirolimus-eluting stent is superior to the zotarolimus-eluting stent for patients receiving routine clinical care," the authors conclude.
The study was supported by Medtronic and Cordis; several authors reported financial relationships with these and other pharmaceutical and medical technology companies.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
